Endra Life Sciences ( (NDRA) ) has released its Q3 earnings. Here is a breakdown of the information Endra Life Sciences presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
ENDRA Life Sciences Inc. is a medical technology company focused on developing devices for liver fat measurement, primarily serving the healthcare sector with innovative solutions for metabolic disease detection. The company recently released its earnings report for the quarter ending September 30, 2025, highlighting significant financial metrics and strategic developments. ENDRA reported a net loss of $1.6 million for the quarter, a decrease from the $2.4 million loss in the same period last year. The company’s operating expenses also saw a reduction, with research and development costs dropping significantly. Despite the financial losses, ENDRA continues to pursue its strategic initiatives, including the development of its liver fat measurement device and the adoption of a digital asset treasury strategy. Looking ahead, ENDRA’s management remains focused on securing additional financing to support its operations and achieve profitability, while continuing to innovate in the medical technology space.